| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer |
|
Medicine details |
|
| Medicine name | trastuzumab emtansine (Kadcyla®) |
| Formulation | 100 mg and 160 mg powder for concentrate for solution for infusion |
| Reference number | 2118 |
| Indication | As a single agent for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/12/2019 |
| NICE guidance | TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer |
| Commercial arrangement | PAS |